Our Sponsor needed to ensure first-inpatient study success in Europe, in a highly competitive oncology field amongst sites and patient availability. A minimum enrolment of 42 patients was required to complete the study.
Caidya Announces Strategic Combination with Simbec-Orion — Learn more here
Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL) Case Study: Efficient Enrolment and Dose Escalation Process Ensures Rapid Access To Critical Data
